According to study findings given in December 2023 at the American Society of Hematology meeting, 67% of patients (36 out of ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

Many individuals with sickle cell anemia undergoing controlled ovarian hyperstimulation (COH) with oocyte cryopreservation ...

INAB READ THE FULL INAB RESEARCH REPORT IN8bio, Inc (NASDAQ:INAB) reported third quarter 2024 financial results and achievements on November 12 th . Activity since the second quarter update was ...

On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...

Good afternoon and welcome to today's conference call for Omeros Corporation. (Operator Instructions) Please be advised that this call is being recorded at the company's request and a replay will be ...

Rebekah Walker, PhD, a first-time participant from the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, shares the offerings and opportunities at the 2024 American Heart ...

Many individuals with sickle cell anemia undergoing controlled ovarian hyperstimulation (COH) with oocyte cryopreser ...

(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.

Now data from the zaltenibart monotherapy stage of the trial will be presented next month in San Diego at the Annual Congress of the American Society of Hematology. We are pleased with the results.

San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...